Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (October 2019)

35 slides from Marinus Pharmaceuticals's investor presentation, Oct 21, 2019

  1. Slide 1: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private

  2. Slide 2: Strategic Overview

    Strategic Overview Ganaxolone: a positive allosteric GABAA modulator with a well-defined MOA designed to treat patients suffering from epilepsy and neuropsychiatric disorders 3 Acute Delivery Chronic Administration ganaxolone Extensive safety record in more than 1,600 subjects both pediatric and adu

  3. Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABAA Receptors

    Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABAA Receptors GNX is a synthetic analog of allopregnanolone GNX is designed to modulate both synaptic and extrasynaptic GABAA receptors to calm over-excited neurons 4

  4. Slide 4: Ganaxolone Development Pipeline

    GANAXOLONE PHASE 1 PHASE 2 PHASE 3 MILESTONES Orphan Refractory Seizure Programs Data Q3 2020 Data 2021 Depressive Disorders* Ganaxolone Development Pipeline Severe PPD TRD Refractory Status Epilepticus 5 PCDH19-Related Epilepsy CDKL5 Deficiency Disorder *Pending regulatory interactions and funding

  5. Slide 5: Orphan Refractory Epilepsy Indications

    Orphan Refractory Epilepsy Indications

  6. Slide 6: Refractory Status Epilepticus (RSE)

    Cause Brain trauma, tumor, stroke, infection, among others Symptoms Seizure lasting >5 minutes or several seizures within 5 minutes with no recovery between seizures Prevalence ~45,000 patients fail 1st line treatment (US)1, 2 Orphan Drug Designation Treatments Few treatments available Benzodiazepin

  7. Slide 7: Goals of a New Treatment for RSE

    Goals of a new treatment for RSE Prevent patient progression towards escalation of treatment (IV anesthetics) Rapid cessation of SE Maintenance of seizure control over study period Goals of a New Therapy for the Treatment of RSE Benzodiazepine Administered Medically induced Coma Established Status E

  8. Slide 8: Status Epilepticus - U.S. Hospital Incidence

    Status Epilepticus - U.S. Hospital Incidence 75K Total SE Patients Annually in U.S. 23 unique ICD-10 codes with some reference to SE Refractory SE patient volumes range from 12.5K to 37.5K Minimum = patients coded as “intractable” in ICD-10 (understated) Maximum = 30%-50% of patients cited as refrac

  9. Slide 9: Rationale for IV Ganaxolone for the Treatment of RSE

    Ganaxolone has demonstrated a broad range of anticonvulsant and psychotherapeutic responses Rationale for IV Ganaxolone for the Treatment of RSE Benzodiazepines are effective in treating acute seizures but not RSE Benzodiazepines are positive allosteric modulators of the synaptic (gamma subunit) GAB

  10. Slide 10: Phase 2 RSE Trial Design

    Treatment Period Loading Dose Maintenance Taper Phase 2 RSE Trial Design Diagnosis of convulsive or non-convulsive SE Failed at least one 2nd line IV AED but not progressed to 3rd line IV anesthetics Bolus plus continuous infusion 2-4 day infusion 18 hour taper Screening Post-treatment Follow-up 24

  11. Slide 11: Phase 2 RSE Trial – Efficacy of IV Ganaxolone

    Phase 2 RSE Trial – Efficacy of IV Ganaxolone 12 Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free at 24 hours from infusion initiation No escalation to additional IV AEDs or IV anesthetics for status relapse at any time through the follow

  12. Slide 12: Target Dose Provided Shorter ICU Time and Greater CGI-I Improvement

    Target Dose Provided Shorter ICU Time and Greater Improvements in CGI-I at Follow-up 13 CGI-I at Final Follow-up Visit (Target Dose) 3: Minimally Improved n=1 2: Much Improved n=1 1: Very Much Improved n=5 *1 patient in Target Dose died due to perforated bowel (not related)

  13. Slide 13: PK Data Supports Target Dosing

    PK Data Supports Target Dosing 14 Modeled PK curves Cohort Dose of GNX/day N Low 500mg/day 5 Medium 650mg/day 4 Target 713mg/day 8 Clinical data presented at NCS 2019 0 3 6 9 0 200 400 600 800 1,000 Time (hrs) G N X P l a s m a C o n c e n t r a t i o n ( n g / m L ) Low (model) Low Dose Patient Rec

  14. Slide 14: Phase 2 RSE Trial - IV Ganaxolone Safety Summary

    2 related in 2 patients 2 severe sedation 13 related in 7 patients 6 mild (2 hypotension, 2 somnolence, 1 urinary retention, 1 hypercarbia) 5 moderate (4 somnolence, 1 hypercarbia) 2 severe (2 sedation) Phase 2 RSE Trial - IV Ganaxolone Safety Summary 15 10 SAEs in 6 patients (also included in AEs)

  15. Slide 15: CDKL5 Deficiency Disorder (CDD)

    Cause Mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome Symptoms Early-onset, treatment refractory seizures, & severe neuro-developmental delay Most can’t walk, talk or care for themselves Suffer from scoliosis, visual impairment, gastrointestinal difficulties

  16. Slide 16: CDD - Phase 2 Trial Design

    Trial Details Baseline Characteristics Endpoints 2 sites in US; 1 site in Italy Median number seizures - 343 (range 101 to 584) Primary: % change in seizure frequency per 28 days relative to baseline 6 females, 1 male – ages 2-16 Confirmed CDKL5 mutation, stable background treatment, >4 seizures per

  17. Slide 17: Efficacy & Safety in Phase 2 Trial in CDD

    Very much improved no change Very much worse Efficacy & Safety in Phase 2 Trial in CDD Data presented at AES 2018 18 Patients experienced a median ‘minimally improved’ rating on CGI-I scale (Clinician rated) correlated with % change in seizure frequency GNX was generally safe and well-tolerated (no

  18. Slide 18: Durable Responses Seen in CDD Phase 2 Extension

    Durable Responses Seen out to 18 Months in CDD Phase 2 Extension 4 of 7 patients entered the extension period Ganaxolone demonstrated preliminary evidence of sustained, long-term (out to 18 months) efficacy in a small cohort of CDD patients Efficacy of existing AEDs and the ketogenic diet in patient

  19. Slide 19: Global Phase 3 Pivotal Study Design

    Global Phase 3 Pivotal Study Design 20 Ganaxolone (600 mg, 3x day maximum) Baseline 6 weeks R 1:1 Historical Control 8 weeks Double-Blind Phase Open-Label Phase Maintenance 13 weeks Titration 4 weeks Titration 4 weeks Open-Label Phase n=100 Ganaxolone (600 mg, 3x day maximum) Placebo Trial Details E

  20. Slide 20: PCDH19-Related Epilepsy

    Cause Inherited mutation of protocadherin 19 (PCDH19) gene. Located on X chromosome Symptoms Early-onset seizures, cognitive and sensory impairment, & psychiatric and behavioral disorders. Seizures last from days to weeks; sensitive to fever Prevalence Affects ~10-12K children US and EU5 Predominant

  21. Slide 21: Significant Seizure Reduction in PCDH19 Phase 2 Trial

    Significant Seizure Reduction in PCDH19 Phase 2 Trial in Patients with Low Allo Levels 25% decrease in median seizure frequency reported in Phase 2 (n=11) Stratification of patients by baseline plasma Allo levels identifies a subpopulation with improved efficacy on GNX When comparing seizure frequen

  22. Slide 22: Biomarker Stratified Phase 3 Pivotal Study in PCDH19

    Biomarker Stratified Phase 3 Pivotal Study in PCDH19 23 R 1:1 PCDH19 (all-patients) n~ 70 Biomarker + n = 50 Low Allo-S Primary efficacy analyses will be conducted using this cohort Biomarker - n~ 20 High Allo-S R 1:1 Ganaxolone Up to 600 mg 3x/day Placebo Ganaxolone Up to 600 mg 3x/day Placebo Gana

  23. Slide 23: Broad Potential for Biomarker Driven Strategy in Rare Genetic Epilepsies

    Broad Potential for Biomarker Driven Strategy in Rare Genetic Epilepsies Depending on results, additional biomarker trials for rare genetic epilepsies may be started Based on the strength of these data, retrospective Allo-S biomarker analyses are being conducted to identify other rare genetic epilep

  24. Slide 24: Allo-S as Potential Biomarker Across Various Genetic Epilepsies

    Allo-S as Potential Biomarker Across Various Genetic Epilepsies 25

  25. Slide 25: PPD Market Segmentation and Value

    Total Annual U.S. PPD Prevalence* ~550K Patients (100%) PPD Market Segmentation and Value *PPD prevalence estimated at ~13% of total 2018 live births of 4.1MM – RBC Analyst report 10/18/18 27 Mild PPD Severe PPD 10% - 20% of moderate and severe PPD patients require hospitalization Moderate PPD

  26. Slide 26: Systematic Evaluation of Ganaxolone Dosing Regimens for PPD

    Systematic Evaluation of Ganaxolone Dosing Regimens for PPD 28 Part 1 Part 2 48-hour IV + 12-hour taper 6-hour IV + 900mg oral + Oral 675mg Oral 675mg/BID for 2 days then 1125 mg for 26 days Early onset of action Good safety Attractive efficacy Low Dose High Dose

  27. Slide 27: IV Ganaxolone: Competitive Profile for Onset of Action, Safety and Ease

    IV Ganaxolone: Competitive Profile for Onset of Action, Safety/Tolerability and Ease of Administration 29 PART 1 48 hour plus 12 hour taper IV provided rapid onset of action that was durable through one month after stopping treatment Dose response observed Multiple efficacy scales (clinician- and pa

  28. Slide 28: HAM-D17 Response and Remission Rates - ITT Population

    HAM-D17 Response and Remission Rates - ITT Population 30 Remission: HAM-D17 > 7 points Response: HAM-D17 decrease > 50% HAM-D17 Response Rates HAM-D17 Remission Rates

  29. Slide 29: Amaryllis – Oral Dosing Showed Decrease in HAM-D17

    Amaryllis – Oral Dosing Showed Encouraging Decrease in HAM-D17 in High Dose Cohort 31 HAM-D17 Reduction Day 2 Day 15 Day 29 Low dose (675mg) 0.8 9.8 12.2 High dose (1125mg) 2.7 9.3 14.5

  30. Slide 30: Favorable Safety Profile Across Regimens

    Favorable Safety Profile Across Regimens 01 Ganaxolone appeared safe and well-tolerated 02 Most common reported AEs were dizziness and sedation 03 No SAEs, no discontinuations due to a TRAE 04 Consistent with prior studies, no reports of syncope or loss of consciousness 32

  31. Slide 31: Multiple Milestones

    Multiple Milestones 33 FDA EOP2 meeting for RSE 1Q 2020 CDD Phase 3 data Q3 2020 Initiate P3 in RSE Mid 2020

  32. Slide 32: Patent Portfolio: Multiple Layers Of Protection

    Orphan Drug protection (SE, CDD, PCDH19) 7 years US / 10 years EU IV formulations and methods of use applications filed patent life 2036 expected IV formulations containing exclusively in-licensed proprietary captisol product patent life 2033 Nanoparticle formulation patents issued in the US (e.g.,

  33. Slide 33: Ganaxolone’s Potential to Offer Continuity of Care

    Ganaxolone’s Potential to Offer Continuity of Care Status Epilepticus, Pediatric Seizure Disorders, Postpartum Depression Attractive orphan indications & large market indications Significant unmet medical need – no or few treatment options Targeted patient populations – understood dysfunctional GABA

  34. Slide 34: Ganaxolone’s Potential to Offer Continuity of Care

    Ganaxolone’s Potential to Offer Continuity of Care Status Epilepticus, Pediatric Seizure Disorders, Postpartum Depression Attractive orphan indications & large market indications. t 7 ‘Significant unmet medical need — no or few treatment options | | Targeted patient populations — understood dysfunct

  35. Slide 35: Thank You

    Thank You

Marinus Pharmaceuticals — Investor Presentation (October 2019) on 6ix